시간 외 거래: 1.16 -0.02 -1.69%

Theriva Biologics Inc (TOVX)

개요 뉴스 가격 이력 토론 예측

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq

Theriva™ Biologics Announces Positive Outcomes from the - GlobeNewswire

Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan

Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World

Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New Orleans - Nasdaq

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewswire

Cancer Therapeutics Innovator Theriva Set for Major Presentation at NeauxCancer 2025 - Stock Titan

Theriva Biologics Reports 2024 Financial Results and Progress - TipRanks

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - The Manila Times

Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - StockTitan

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - The Manila Times

Cancer Therapeutics Company Theriva Sets Key Investor Presentation DateWhat to Expect - StockTitan

Theriva Biologics Inc Inc. (TOVX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga

Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India

Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK

Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada

Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire

Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan

Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa

Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com

Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World

Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks

Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire

Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

What's Going On With Theriva Biologics Stock Friday? - MSN

Theriva Biologics Expands Stock Plans and Share Authority - TipRanks

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - The Manila Times

Theriva Biologics gains EU orphan drug status for eye cancer treatment - Investing.com

Theriva Biologics Announces Orphan Medicinal Product - GlobeNewswire

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - StockTitan

Check out these key findings about Theriva Biologics Inc (TOVX) - SETE News

Theriva Biologics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Was Theriva Biologics Inc (TOVX)’s session last reading good? - US Post News

Market cap of Theriva Biologics Inc [TOVX] reaches 4.06M – now what? - The DBT News

Closing Figures: Theriva Biologics Inc (TOVX)’s Positive Finish at 1.79, Up 44.35 - The Dwinnex

Theriva reports progress in phase 1b/2a trial of SYN-004 By Investing.com - Investing.com South Africa

Synthetic Biologics stock plunges to 52-week low of $1.24 By Investing.com - Investing.com Australia

Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com

Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga

Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients - Seeking Alpha

Theriva Biologics Advances SYN-004 in Clinical Trial - TipRanks

Theriva reports progress in phase 1b/2a trial of SYN-004 - Investing.com India

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Manila Times

TOVX과 유사한 종목